Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Exp Clin Cancer Res
Asıl Yazarlar: Noblejas-López, María del Mar, Nieto-Jimenez, Cristina, Burgos, Miguel, Gómez-Juárez, Mónica, Montero, Juan Carlos, Esparís-Ogando, Azucena, Pandiella, Atanasio, Galán-Moya, Eva M., Ocaña, Alberto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717344/
https://ncbi.nlm.nih.gov/pubmed/31470872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1387-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller